ClinicalTrials.gg
Not yet recruitingNCT05620485CDCPSUpdated Nov 17, 2022

Timing of Operation in Children With a Prenatal Diagnosis of Choledochal Cyst

An interventional study of laparoscopic-assisted CDC excision and hepaticojejunostomy in Choledochal Cyst, sponsored by Guangzhou Women and Children's Medical Center. Not yet recruiting. Open to participants aged 0 Months to 3 Months. Per ClinicalTrials.gov, last updated 2022-11-17.

Sponsored by Guangzhou Women and Children's Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
0 Months to 3 Months
Sex
All
01

Study summary

In this prospective study, we tried to select the operation time according to the cyst size and evaluate the treatment effect.

Read the detailed description

A choledochal cyst (CDC) is a congenital anomaly of the biliary system, which is more common in the Asian population. If a CDC is not diagnosed and treated promptly, it often leads to a series of serious complications, including cholangitis, cyst rupture, cholestatic cirrhosis, and even cholangiocarcinoma. Infants with a postnatal diagnosis of CDC often present with symptoms, and to avoid the occurrence of serious complications, operative correction should be performed as soon as possible when their clinical conditions allow. However, in the current era with the improvement of prenatal screening technology, an increasing number of choledochal cysts are diagnosed prenatally in the fetus. In developed countries, as many as 15% of choledochal cysts are found before birth. Some of these children receive intervention when they are asymptomatic at an early stage, while some have progressed to CDC-related symptoms before operative correction. The timing of operation for children with a prenatal diagnosis of CDC remains controversial. The investigators previous study showed that it is more advantageous to receive surgical treatment in the asymptomatic period for patients with prenatally diagnosed CDC. In addition, the age at operation (months) appears to be unrelated to intraoperative and postoperative complications, which is distinct from previous studies. More interestingly, the investigators found that a specific cyst size (length > 5.2 cm and width > 4.1 cm) suggested that clinical symptoms might appear and that the surgery should be performed as soon as clinically safe to proceed. Therefore, in this study, the investigators tried to select the operation time according to the cyst size and evaluate the treatment effect.

02

Conditions studied

  • Choledochal Cyst

Browse trials for

03

In context

Choledochal Cyst

22 studies on the registry are indexed under Choledochal Cyst; 10 are open to participants now.

Browse Choledochal Cyst studies →

Lead sponsor

Guangzhou Women and Children's Medical Center is the lead sponsor of 58 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Months to 3 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Infants with a prenatal and postnatal diagnosis with CDC
  2. Prenatal and postnatal hepatobiliary ultrasound data were complete
  3. Age of visit \< 3 months

Exclusion criteria

Exclusion Criteria:

Unable to tolerate surgery after birth

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    prenatally diagnosed CDC

    All patients received laparoscopic-assisted CDC excision and hepaticojejunostomy.

    Procedure: laparoscopic-assisted CDC excision and hepaticojejunostomy

Interventions

  • Procedurelaparoscopic-assisted CDC excision and hepaticojejunostomy

    After birth, the liver and gallbladder ultrasound were regularly rechecked. If the maximum diameter of the cyst was greater than 5 cm, surgery was performed.

06

What researchers measure

Primary outcomes

  1. preoperative complications

    number of participants progressed to CDC-related symptoms before operative intervention

    Time frame: pre-intervention

  2. preoperative complications

    number of participants with cyst rupture before operative intervention

    Time frame: pre-intervention

  3. preoperative complications

    aspartate aminotransferase (U/L)

    Time frame: 1 week before surgery

  4. preoperative complications

    alanine aminotransferase (U/L)

    Time frame: 1 week before surgery

  5. preoperative complications

    γ-glutamyl transpeptidase (U/L)

    Time frame: 1 week before surgery

  6. preoperative complications

    Serum Bilirubin (μmol/L)

    Time frame: 1 week before surgery

  7. short-term complications

    number of participants with post-operative anastomotic leak

    Time frame: 1 weak after surgery

  8. short-term complications

    number of participants with postoperative hemorrhage

    Time frame: 1 weak after surgery

  9. short-term complications

    aspartate aminotransferase (U/L)

    Time frame: 1 weak after surgery

  10. short-term complications

    alanine aminotransferase (U/L)

    Time frame: 1 weak after surgery

  11. short-term complications

    γ-glutamyl transpeptidase (U/L)

    Time frame: 1 weak after surgery

  12. short-term complications

    Serum Bilirubin (μmol/L)

    Time frame: 1 weak after surgery

  13. short-term complications

    aspartate aminotransferase (U/L)

    Time frame: 3 months after surgery

  14. short-term complications

    alanine aminotransferase (U/L)

    Time frame: 3 months after surgery

  15. short-term complications

    γ-glutamyl transpeptidase (U/L)

    Time frame: 3 months after surgery

  16. short-term complications

    Serum Bilirubin (μmol/L)

    Time frame: 3 months after surgery

  17. short-term complications

    aspartate aminotransferase (U/L)

    Time frame: 6 months after surgery

  18. short-term complications

    alanine aminotransferase (U/L)

    Time frame: 6 months after surgery

  19. short-term complications

    γ-glutamyl transpeptidase (U/L)

    Time frame: 6 months after surgery

  20. short-term complications

    Serum Bilirubin (μmol/L)

    Time frame: 6 months after surgery

  21. short-term complications

    number of participants with postoperative wound infection

    Time frame: 1 month after surgery

  22. Long-term complications

    number of participants with anastomotic stricture

    Time frame: 3 years after surgery

Secondary outcomes

  1. length of stay

    length of hospital stay

    Time frame: 1 month after surgery

  2. duration of ventilator support

    duration of ventilator support

    Time frame: 1 month after surgery

  3. length of nutritional support in hospital

    length of nutritional support in hospital

    Time frame: 1 month after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2022; primary completion for Nov 2025, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2022
First posted
Nov 17, 2022
StartEst.
Nov 15, 2022
Primary completionEst.
Nov 15, 2025
CompletionEst.
Nov 15, 2026
Last update
Nov 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05620485
Lead sponsor
Guangzhou Women and Children's Medical Center
Responsible party
Xisi Guan (Clinical attending doctor, Guangzhou Women and Children's Medical Center) — Principal investigator
First posted
Nov 17, 2022
Start date
Nov 15, 2022 (estimated)
Primary completion
Nov 15, 2025 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Nov 17, 2022

Study contacts

xisi guan
Contact
545280987@qq.com
13926155230

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion